Recursion Pharmaceuticals, Inc. (RXRX) - Comprehensive Stock Analysis & Investment Research
Deep dive into Recursion Pharmaceuticals, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.
Recursion Pharmaceuticals, Inc. Investment Summary
When evaluating whether Recursion Pharmaceuticals, Inc. (RXRX) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.
Company Profile
Recursion Pharmaceuticals, Inc. (RXRX) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $2 billion, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.
Financial Performance Analysis
Our comprehensive financial analysis covers Recursion Pharmaceuticals, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...
AI Price Predictions
Get AI-powered 7-day, 30-day and 90-day price forecasts for Recursion Pharmaceuticals, Inc. along with confidence scores and detailed analysis...
Investment Considerations
Expert analysis of whether Recursion Pharmaceuticals, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...
Corporate Identity
Recursion Pharmaceuticals, Inc. (Stock Symbol: RXRX) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.
Leadership & Workforce
Detailed information about Recursion Pharmaceuticals, Inc.'s leadership team, workforce size, and organizational structure...
Market Classification
Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Recursion Pharmaceuticals, Inc....
Sector & Industry Analysis
In-depth sector dynamics and industry context for Recursion Pharmaceuticals, Inc....
Revenue & Growth Analysis
Recursion Pharmaceuticals, Inc. generates annual revenues of $66 million , representing an emerging company in its growth phase.
Profitability Metrics
Net profit margin, gross margin, and operating margin analysis for Recursion Pharmaceuticals, Inc....
Market Valuation
P/E ratio, price-to-book, and valuation multiples for Recursion Pharmaceuticals, Inc....
Return Metrics
Return on equity (ROE), return on assets (ROA), and capital efficiency for Recursion Pharmaceuticals, Inc....
Strategic Market Position
Recursion Pharmaceuticals, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.
Industry Competitive Landscape
Recursion Pharmaceuticals, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.
Operational Efficiency
The company currently shows negative free cash flow of $-326 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.
Asset Utilization Efficiency
Asset turnover ratio of 0.05x indicates lower asset turnover that may reflect the industry's capital-intensive nature or potentially underutilized assets. Companies with low turnover typically depend on strong margins to generate adequate returns on capital.
Financial Strength & Leverage
Current ratio of 5.47 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.